Synthetic Biologics (SYN) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts SYN Hot Sheet
Join SI Premium – FREE
Synthetic Biologics (NYSE: SYN) reported Q3 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Synthetic Biologics (SYN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
- Valero Energy (VLO) PT Raised to $467 at UBS Into Q3 Earnings
- BlackBerry stock rises on QNX software momentum
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
